Healio

Nerandomilast reduces FVC decline, has ‘manageable’ adverse events in IPF at 52 weeks

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Two differing nerandomilast doses were assessed against ...
Business Insider

Pooled data presented at ERS: nerandomilast monotherapy linked to nominally significant reduction in risk of death in IPF and PPF

A new pooled analysis of the FIBRONEER™-IPF and FIBRONEER™-ILD trials resulted in a nominally significant reduction in the risk of death by 59% in patients who received 18mg nerandomilast without ...
Healio

Nerandomilast reduces FVC decline in US patients with IPF

Please provide your email address to receive an email when new articles are posted on . Both the 18 mg and 9 mg nerandomilast groups had smaller degrees of FVC decline vs. placebo in the U.S. subgroup ...
MedPage Today

Novel PDE4 Inhibitor Slows IPF Progression

Novel oral agent nerandomilast slowed progression of idiopathic pulmonary fibrosis (IPF), even atop background antifibrotic therapy, the phase III FIBRONEER-IPF trial showed. Forced vital capacity ...
The Bakersfield Californian

Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study

Topline data from FIBRONEER™-IPF show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in Forced Vital Capacity [mL] at week 52 ...
FOX59 News

Global phase III trials demonstrate that nerandomilast slowed lung function decline in IPF and PPF, with similar discontinuation rates to placebo

Boehringer Ingelheim announced today detailed findings from the Phase III FIBRONEER™-IPF and FIBRONEER™-ILD trials. These studies evaluated nerandomilast, an investigational oral, preferential ...
MarketWatch

U.S. FDA approves Boehringer's JASCAYD(R) (nerandomilast tablets) as first new treatment option for adults with IPF in over a decade

The MarketWatch News Department was not involved in the creation of this content. Ingelheim, Germany/Ridgefield, Connecticut, U.S. -- Idiopathic pulmonary fibrosis (IPF) is a progressive disease, ...